false 0001347178 0001347178 2025-01-25 2025-01-25 0001347178 us-gaap:CommonStockMember 2025-01-25 2025-01-25 0001347178 vnda:SeriesAJuniorParticipatingPreferredStockPurchaseRightMember 2025-01-25 2025-01-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 27, 2025 (January 25, 2025)

 

 

VANDA PHARMACEUTICALS INC.

(Exact name of Registrant as specified in its charter)

 

 

 

Delaware   001-34186   03-0491827
(State or other jurisdiction
of incorporation)		  

(Commission

File No.)

   (IRS Employer
Identification No.)

2200 Pennsylvania Avenue NW

Suite 300E

Washington, DC 20037

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (202) 734-3400

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   VNDA   The Nasdaq Global Market
Series A Junior Preferred Stock Purchase
Right, par value $0.001 per share		   —   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 7.01.

Regulation FD Disclosure.

On January 25, 2025, Vanda Pharmaceuticals Inc. (“Vanda”) issued a post on the social media platform X regarding the filing of a new drug application for tradipitant for the treatment of motion sickness. The full text of the post was as follows:

“80 years ago on June 6, 1944, during WWII, Allied troops landed in Normandy. Each soldier ‘was given seven sticks of chewing gum, four boxes of matches, a box of body insecticide, three boxes of D rations, pipe, cigarette and chewing tobacco, water purification tablets, a carton of cigarettes or cigarette makings, one razor blade, a tin of canned heat, 12 seasickness pills and two vomit bags’ (New York Daily News, 1944).

Motion sickness is not just a common everyday disabling condition but it can also impact national security. 80 years later Vanda has applied for the approval of a new drug, tradipitant, to treat motion sickness.”

The information furnished pursuant to this Item 7.01 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 27, 2025     VANDA PHARMACEUTICALS INC.
    By:  

/s/ Timothy Williams

    Name:   Timothy Williams
    Title:   Senior Vice President, General Counsel and Secretary
v3.24.4
Document and Entity Information
Jan. 25, 2025
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001347178
Document Type 8-K
Document Period End Date Jan. 25, 2025
Entity Registrant Name VANDA PHARMACEUTICALS INC.
Entity Incorporation State Country Code DE
Entity File Number 001-34186
Entity Tax Identification Number 03-0491827
Entity Address, Address Line One 2200 Pennsylvania Avenue NW
Entity Address, Address Line Two Suite 300E
Entity Address, City or Town Washington
Entity Address, State or Province DC
Entity Address, Postal Zip Code 20037
City Area Code (202)
Local Phone Number 734-3400
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol VNDA
Security Exchange Name NASDAQ
Series A Junior Participating Preferred Stock Purchase Right [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Series A Junior Preferred Stock PurchaseRight, par value $0.001 per share
Trading Symbol —
Security Exchange Name NASDAQ
Vanda Pharmaceuticals (NASDAQ:VNDA)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse Vanda Pharmaceuticals
Vanda Pharmaceuticals (NASDAQ:VNDA)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse Vanda Pharmaceuticals